Angiotech Pharmaceuticals Inc

Angiotech Pharmaceuticals — Q2 2008 Earnings Presentation

15 slides from Angiotech Pharmaceuticals's earnings presentation, Jul 28, 2008

  1. Slide 1: Second Quarter 2008 Results

    Exhibit 99.1 Second Quarter 2008 Results July 28, 2008

  2. Slide 2: Financial Review

    Financial Review Tom Bailey, CFO

  3. Slide 3: Forward-Looking Statements

    3 Forward-Looking Statements Statements contained in this presentation that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects” and similar expressions, constitu

  4. Slide 4: Financial Information

    4 Financial Information This presentation contains the condensed financial statements derived from the unaudited consolidated interim financial statements for the three-month periods ended June 30, 2008, and 2007. Full unaudited consolidated interim financial statements and Management’s Discussion a

  5. Slide 5: Proxy Statement Legend

    Proxy Statement Legend Additional Information and Where to Find It – In connection with the proposed establishment of separate royalty and operating businesses, Angiotech filed a preliminary proxy statement with the SEC. The preliminary proxy statement is not yet final and will be amended. Sharehold

  6. Slide 6: Q2:08 Financial Results: Summary

    6 Q2:08 Financial Results Summary Total revenue (adjusted): $76.1M – vs. $76.7M in Q1:08 – vs. $75.3M in Q2:07 Product revenues: $50.5M – vs. $47.7M in Q1:08 – vs. $45.4M in Q2:07 Royalty revenues: $25.5M – vs. $28.9M in Q1:08 – vs. $29.9M in Q2:07

  7. Slide 7: Q2:08 Financial Results: Summary

    7 Q2:08 Financial Results Summary Adjusted EBITDA: $5.9M – vs. $9.3M in Q1:08 – vs. $15.6M in Q2:07 GAAP EPS: ($0.31)* Adjusted EPS: ($0.09)* Cash and investments: $81.0M – vs. $90.1M in Q1:08 – vs. $144.2M in Q2:07 * Corrected from ($0.26) ** Corrected from ($0.04)

  8. Slide 8: Q2:08 Financial Results: Product Sales

    Q2:08 Financial Results Highlights: Product Sales Strong product sales performance continues – Medical product sales > $50M – +11% vs. Q2:07 (Q2:07 on adjusted basis) – +5% sequential growth vs. Q1:08 – Broad-based achievement of revenue plan • Every business line at or above our Q2 and H2 targets •

  9. Slide 9: Q2:08 Financial Results: Cash Flow, Margins

    Q2:08 Financial Results Highlights: Cash Flow, Margins Improving operating margins – Gross margin 48% (vs. 46% in Q1) – Leveraging sales growth: SGA @ $23.6M in Q2:08 vs. $23.3M in Q1:08 vs. $23.5M in Q4:07 – Adjusted EBITDA at $5.9M • Lower royalty revenue (-$3.4M) • Higher R & D (+$2.5M) – Vascula

  10. Slide 10: Second Quarter Summary and Conclusions

    Second Quarter Summary and Conclusions Dr. Bill Hunter, President and CEO

  11. Slide 11: Q2:08 Business Highlights

    11 Q2:08 Business Highlights Products 5-FU Central Venous Catheter – April 17, 2008 received 510(k) marketing clearance from FDA – H2:08 expected product launch – Developing 5-FU for other product applications • Leveraging our investment in outstanding clinical data set Quill SRS – Building the foun

  12. Slide 12: Q2:08 Business Highlights: Royalty Revenue

    12 Q2:08 Business Highlights Royalty Revenue Zilver® PTX™ Paclitaxel-eluting Peripheral Stent – June 11, 2008: Our partner Cook announces positive interim results from registry arm of clinical studies – Interim data at six and 12 months; 435 and 200 patients respectively – Corresponding EFS rates: 9

  13. Slide 13: Angiotech Revenue Mix

    Angiotech Revenue Mix TAXUS vs. ANPI Medical Products Revenue ANPI: Latest 12 Months Stock Price ($ millions) Q3 07 Q4 07 Q1 08 Q2 08 BSX Worldwide Taxus Revenue $448 $435 $428 $382 % Q-o-Q growth -22% -14% -9% -13% ANPI Royalty Revenue* $26.6 $27.2 $28.9 $25.5 % Q-o-Q growth -39% -29% -12% -15% ANP

  14. Slide 14: Conclusions

    Conclusions Delivering Value, Mitigating Risk Strong revenue quarter in our operating businesses – Greater than $50M in medical products revenue – Sales reorganization and strategy is working Promoted brand strategy is working – Differential growth of our “best in class” products – Quill SRS: contin

  15. Slide 15: Angiotech

    = x Angiotech Redefining Success~ 1 2 BeemeARMACEUTICALS inc =n aE

Angiotech Pharmaceuticals — Q2 2008 Earnings Presentation on 6ix